Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Liabilities and Shareholders Equity: 2020-2024

Historic Liabilities and Shareholders Equity for Relay Therapeutics (RLAY) over the last 5 years, with Dec 2024 value amounting to $871.3 million.

  • Relay Therapeutics' Liabilities and Shareholders Equity fell 27.97% to $670.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 billion, marking a year-over-year decrease of 9.40%. This contributed to the annual value of $871.3 million for FY2024, which is 3.24% up from last year.
  • Latest data reveals that Relay Therapeutics reported Liabilities and Shareholders Equity of $871.3 million as of FY2024, which was up 3.24% from $844.0 million recorded in FY2023.
  • Over the past 5 years, Relay Therapeutics' Liabilities and Shareholders Equity peaked at $1.1 billion during FY2022, and registered a low of $799.8 million during FY2020.
  • In the last 3 years, Relay Therapeutics' Liabilities and Shareholders Equity had a median value of $871.3 million in 2024 and averaged $938.3 million.
  • In the last 5 years, Relay Therapeutics' Liabilities and Shareholders Equity rose by 26.08% in 2021 and then declined by 23.26% in 2023.
  • Relay Therapeutics' Liabilities and Shareholders Equity (Yearly) stood at $799.8 million in 2020, then rose by 26.08% to $1.0 billion in 2021, then increased by 9.06% to $1.1 billion in 2022, then fell by 23.26% to $844.0 million in 2023, then rose by 3.24% to $871.3 million in 2024.